Advertisement
U.S. markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
89.30-1.64 (-1.80%)
At close: 04:00PM EST
89.50 +0.20 (+0.22%)
After hours: 05:23PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close90.94
Open89.89
Bid89.16 x 1400
Ask89.31 x 900
Day's Range87.93 - 90.40
52 Week Range87.93 - 136.91
Volume604,121
Avg. Volume721,435
Market Cap21.228B
Beta (5Y Monthly)0.23
PE Ratio (TTM)7.33
EPS (TTM)12.18
Earnings DateMar 20, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2022
1y Target Est126.47
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
25% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BNTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioNTech SE
    Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more